Increasing effectiveness of conservative treatment of Peyronie’s disease

Abstract

The study objective is to investigate the effectiveness of conservative treatment of Peyronie’s disease using antifibrotic agents.Materials and methods. The study included 32 patients aged 44–65 years with diagnosed Peyronie’s disease. The patients were examined using the International Index of Erectile Function, Visual Analog Scale, tunica albuginea of the penis elasticity testing, ultrasound examination (with intracavernous pharmacological testing and dynamic spiral tomography if necessary). The patients were divided into 2 groups. The patients in the treatment group (n = 16) received magnetic laser therapy at the area of the plaque with the “Mustang-urolog” device, as well as vacuum laser treatment with the “Yarovit” device and bovhyaluronidase azoximer as injections and later suppositories. In the comparison group (n = 16), similar therapy was used without bovhyaluronidase azoximer. Control examination was performed 3 months later. If conservative treatment was ineffective, the patients were forwarded to surgical treatment.Results. As a result of conservative treatment, density of the tunica albuginea and cavernous bodies, structure of the cavernous bodies improved; the International Index of Erectile Function increased, and pain intensity decreased. In the treatment group, a stronger tendency toward improvement was observed compared to the control group. Decrease in the plaque size was observed in 63.3 % of the patients in the treatment group and in 43.7 % of the patients in the control group. At the control examination, plaques weren’t detected in 6 and 3 patients, respectively.Conclusion. Conservative treatment is effective in patients with early stage of Peyronie’s disease with moderate curvature of the penis (<30°) and plaque size <2 cm. We recommend including bovhyaluronidase azoximer in the combination treatment regimen of these patients for increased effectiveness.

Keywords

• peyronie’s disease
• conservative treatment
• bovhyaluronidase azoximer
• antifibrotic agents